The aim – to compare the dynamics of the cardiac troponin I in patients with stable angina after elective percutaneous coronary intervention (PCI) depending on method of drug cardioprotection.
Material and metods. The prospective, open-label randomized clinical study included 139 patients with chronic ischemic heart disease and stable angina. They were randomized into the following groups: A (control) receiving standard treatment and clopidogrel 300 mg before percutaneous coronary intervention (PCI); B – receiving rosuvastatin in the loading dose (40 mg) 24 h before PCI; C – receiving rosuvastatin and trimetazidine 140 mg 24 h before PCI; D – receiving only trimetazidine 140 mg in addition to standard treatment.
Results. We found no statistically significant differences of the troponin I levels at 12 hours post-PCI in patients without periprocedural myocardial injury among all study groups (P=0.347). Patients with confirmed periprocedural myocardial injury 12 hours (P=0.010) and 24 hours post-PCI (P=0.009) had significantly different troponin I serum levels in all groups of patients.
Conclusions. At the same time, the mean serum level troponin I did not significantly differ in the interventional group of reload statin and combined therapy. Only in the group receiving combination of bolus rosuvastatin and trimetazidine, we observed reduction of serum troponin I values by 0.062±0.05 ng/ml after PCI.